Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
At present, PD-L1 scoring is the gold standard in evaluating a cancer patient's suitability for receiving PD-1/PD-L1 checkpoint inhibitor immunotherapy (CIT). Either tumor proportion score (TPS) or combined positive score (CPS) can be used to select head and neck squamous cell carcinoma (HNSCC)...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024000347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553787125235712 |
|---|---|
| author | Madhusudan Roy Jing-Tang Lin Sohidul Mondal Mei-Chun Lin Chih-Yu Leu Yen-Lin Huang Chen-Yuan Dong Pei-Jen Lou |
| author_facet | Madhusudan Roy Jing-Tang Lin Sohidul Mondal Mei-Chun Lin Chih-Yu Leu Yen-Lin Huang Chen-Yuan Dong Pei-Jen Lou |
| author_sort | Madhusudan Roy |
| collection | DOAJ |
| description | At present, PD-L1 scoring is the gold standard in evaluating a cancer patient's suitability for receiving PD-1/PD-L1 checkpoint inhibitor immunotherapy (CIT). Either tumor proportion score (TPS) or combined positive score (CPS) can be used to select head and neck squamous cell carcinoma (HNSCC) patients for immunotherapy. However, the current clinical workflow only uses one histological section for PD-L1 scoring. The considerable under-sampling of a patient's tissue may lead to an inaccurate PD-L1 score, potentially affecting treatment outcomes. In this study, we selected formalin-fixed, paraffin-embedded (FFPE) tissue blocks from five HNSCC patients. The thickness of each of these tissue blocks allowed us to determine the tumor proportion score (TPS) and combined positive score (CPS) at five depths with adjacent layers separated by 500 μm. We found that although there are variations of scores among different tissue sections, the scores are generally consistent across the tissue block from each patient. We also compared TPS and CPS values at different sampling frequencies with a single section and sections separated by 1000, 1500, and 2000 μm. We found that in all cases, the values all fall within one standard deviation of the average values of all five depths. Considering the different threshold values of TPS and CPS for treatment decisions, our results suggest that in cases where the patients' scores are close to that of the threshold values, scoring of two histological sections separated by 2000 μm should be considered. |
| format | Article |
| id | doaj-art-f79570fa40fc421b80974a432d69fa61 |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-f79570fa40fc421b80974a432d69fa612025-01-09T06:15:16ZengElsevierOral Oncology Reports2772-90602024-03-019100188Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapyMadhusudan Roy0Jing-Tang Lin1Sohidul Mondal2Mei-Chun Lin3Chih-Yu Leu4Yen-Lin Huang5Chen-Yuan Dong6Pei-Jen Lou7Department of Physics, National Taiwan University, Taipei, 106, TaiwanDepartment of Physics, National Taiwan University, Taipei, 106, TaiwanDepartment of Physics, National Taiwan University, Taipei, 106, TaiwanDepartment of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, 100, TaiwanDepartment of Medical Education, National Taiwan University College of Medicine, Taipei, 100, TaiwanDepartment of Pathology, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, 106328, Taiwan; Corresponding author.Department of Physics, National Taiwan University, Taipei, 106, Taiwan; Corresponding author.Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, 100, Taiwan; Corresponding author.At present, PD-L1 scoring is the gold standard in evaluating a cancer patient's suitability for receiving PD-1/PD-L1 checkpoint inhibitor immunotherapy (CIT). Either tumor proportion score (TPS) or combined positive score (CPS) can be used to select head and neck squamous cell carcinoma (HNSCC) patients for immunotherapy. However, the current clinical workflow only uses one histological section for PD-L1 scoring. The considerable under-sampling of a patient's tissue may lead to an inaccurate PD-L1 score, potentially affecting treatment outcomes. In this study, we selected formalin-fixed, paraffin-embedded (FFPE) tissue blocks from five HNSCC patients. The thickness of each of these tissue blocks allowed us to determine the tumor proportion score (TPS) and combined positive score (CPS) at five depths with adjacent layers separated by 500 μm. We found that although there are variations of scores among different tissue sections, the scores are generally consistent across the tissue block from each patient. We also compared TPS and CPS values at different sampling frequencies with a single section and sections separated by 1000, 1500, and 2000 μm. We found that in all cases, the values all fall within one standard deviation of the average values of all five depths. Considering the different threshold values of TPS and CPS for treatment decisions, our results suggest that in cases where the patients' scores are close to that of the threshold values, scoring of two histological sections separated by 2000 μm should be considered.http://www.sciencedirect.com/science/article/pii/S2772906024000347Head and neck squamous cell carcinoma (HNSCC)ImmunotherapyPD-L1 labelingTumor proportion score (TPS)Combined positive score (CPS) |
| spellingShingle | Madhusudan Roy Jing-Tang Lin Sohidul Mondal Mei-Chun Lin Chih-Yu Leu Yen-Lin Huang Chen-Yuan Dong Pei-Jen Lou Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy Oral Oncology Reports Head and neck squamous cell carcinoma (HNSCC) Immunotherapy PD-L1 labeling Tumor proportion score (TPS) Combined positive score (CPS) |
| title | Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy |
| title_full | Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy |
| title_fullStr | Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy |
| title_full_unstemmed | Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy |
| title_short | Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy |
| title_sort | depth dependent pd l1 sampling of head and neck squamous cell carcinoma hnscc implications for pd 1 pd l1 checkpoint inhibitor immunotherapy |
| topic | Head and neck squamous cell carcinoma (HNSCC) Immunotherapy PD-L1 labeling Tumor proportion score (TPS) Combined positive score (CPS) |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024000347 |
| work_keys_str_mv | AT madhusudanroy depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy AT jingtanglin depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy AT sohidulmondal depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy AT meichunlin depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy AT chihyuleu depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy AT yenlinhuang depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy AT chenyuandong depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy AT peijenlou depthdependentpdl1samplingofheadandnecksquamouscellcarcinomahnsccimplicationsforpd1pdl1checkpointinhibitorimmunotherapy |